EcoDrugPlus

Androgen Receptor-Like

Ensembl ID : ENSPNAG00000024394
Gene Symbol: LOC108436713
2 Cross references
206 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSPNAG00000030018
Gene Symbol: AGTR1
3 Cross references
198 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSPNAG00000024691
Gene Symbol: AGTR1
3 Cross references
144 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSPNAG00000012191
Gene Symbol: AGTR2
4 Cross references
169 Possible Orthologues:

Apelin Receptor A-Like

Ensembl ID : ENSPNAG00000024511
Gene Symbol: LOC108443364
3 Cross references
171 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSPNAG00000020897
Gene Symbol: APEX1
3 Cross references
212 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSPNAG00000027136
Gene Symbol: ALOX5
3 Cross references
221 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSPNAG00000006240
Gene Symbol: ALOX5AP
3 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSPNAG00000018465
Gene Symbol: LOC108434653
3 Cross references
198 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSPNAG00000010650
Gene Symbol: AVPR1A
3 Cross references
195 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSPNAG00000025040
Gene Symbol: AVPR1A
4 Cross references
132 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSPNAG00000020379
Gene Symbol: AVPR2
3 Cross references
178 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).